The first participant with Angelman syndrome has now been dosed in Ionis’ Phase 3 REVEAL trial of ION582.  

"Dosing the first person with Angelman syndrome in our pivotal REVEAL study marks an important milestone for this underserved community, who currently have no approved disease modifying treatments," said Holly Kordasiewicz, Ph.D., senior vice president of neurology, Ionis.

Read the press release and community letter here:

If you have questions about trial sites or participation, please reach out directly to Ionis at (844) 285-7172 or IonisION582-CS2@clinicaltrialmedia.com

Understanding clinical trials isn’t easy, especially when you're making decisions for someone you love. ASF and FAST, in partnership with Ultragenyx, have created a video FAQ library to help families navigate the details of GTX-102 and the Aspire clinical trial. These short videos address common questions and give caregivers the information they need to feel confident about their choices, now and in the future. 

View the full library:

So much has happened this month, and it’s all thanks to our incredible community. From coast-to-coast bike rides to heartfelt golf outings, families and supporters have come together to raise funds and awareness for Angelman syndrome.  

Here's a look at what’s been happening across the country:  

• Harper’s Hope Golf Event
• Charlie’s Angels Chari-Tee
• Go Gus Go Golf Outing
• Rally for a Cure for AS
• Bike 4 Briar

Thanks for reading, and please share this email with anyone in your network who would be interested in receiving our updates.